Drug details
Tresiba (insulin degludec injection)
type of Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins
Tresiba (insulin degludec injection) is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.
This drug may have the following side effects:
- headache,
- runny or stuffy nose,
- diarrhea.
- itching,
- allergic reactions,
- weight gain,
- injection site reactions,
- rash,
- swelling,
- upper respiratory tract infection,
- sinusitis,
- low blood sugar (hypoglycemia),
- body fat redistribution (lipodystrophy),
- upset stomach or stomach pain, and
The following drugs are related to Tresiba, either as a replacement or used together:
- Brenzavvy (bexagliflozin tablets)
- Qternmet XR (dapagliflozin, saxagliptin, and metformin hydrochloride)
- Zegalogue (dasiglucagon injection)
- Lantidra (donislecel-jujn allogeneic pancreatic islet cellular)
- Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets)
- Toujeo U 300 (insulin glargine injection for subcutaneous use)
- Novolin N (insulin isophane)
- Lyumjev (insulin lispro-aabc injection)
- Myxredlin (insulin regular human)
- Rybelsus (semaglutide tablets)
- Tzield (teplizumab-mzwv injection, for intravenous use)